Sort   by:  
 Page size 
UnknownCaplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis.
Not available
S-EPMC8095153 | biostudies-literature
UnknownTricyclic SpiroLactams Kill Mycobacteria In Vitro and In Vivo by Inhibiting Type II NADH Dehydrogenases.
Not available
S-EPMC9791652 | biostudies-literature
UnknownCaplacizumab improves clinical outcomes and is well tolerated across clinically relevant subgroups of patients with immune-mediated thrombotic thrombocytopenic purpura.
Not available
S-EPMC11362790 | biostudies-literature
UnknownLong-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study.
Not available
S-EPMC9827931 | biostudies-literature
UnknownClinical phenotypes and outcomes associated with SARS-CoV-2 variant Omicron in critically ill French patients with COVID-19.
Not available
S-EPMC9555693 | biostudies-literature
UnknownClinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variants BA.2, BA.5 and BQ.1.1 in critically ill patients with COVID-19: a prospective, multicenter cohort study.
Not available
S-EPMC10404579 | biostudies-literature
UnknownDesign specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies.
Not available
S-EPMC12316993 | biostudies-literature
UnknownSeladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
Not available
S-EPMC10344437 | biostudies-literature
UnknownClinical Phenotypes of Critically Ill Patients with COVID-19 Infected with Omicron: A Nationwide Prospective Cohort Study.
Not available
S-EPMC12855665 | biostudies-literature
UnknownCOVID-19 associated pulmonary aspergillosis in critically-ill patients: a prospective multicenter study in the era of Delta and Omicron variants.
Not available
S-EPMC11043290 | biostudies-literature
Sort   by:  
 Page size